• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Syndros (dronabinol oral solution)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Syndros (dronabinol oral solution)

  • Profile

Profile

Contact Information

Contact: Benuvia Therapeutics Inc.
Website: http://www.syndros.com/

Currently Enrolling Trials

    Show More

    General Information

    Syndros is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Dronabinol has complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol. 

    Syndros is specifically indicated for 1) anorexia associated with weight loss in patients with acquired immune deficiency syndrome (AIDS); and 2) nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. 

    Mechanism of Action

    Syndros is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Dronabinol has complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol. 

    Side Effects

    Adverse effects associated with the use of Syndros may include, but are not limited to, the following:

    • dizziness
    • euphoria
    • paranoid reaction
    • somnolence
    • thinking abnormal
    • abdominal pain
    • nausea
    • vomiting

    Dosing/Administration

    Syndros is supplied as a solution for oral administration. The recommended dose is as follows:

    Anorexia associated with weight loss in adult patients with AIDS:

    Starting dosage: The recommended adult starting dosage of Syndros is 2.1 mg orally twice daily, one hour before lunch and one hour before dinner. In elderly patients, consider initiating Syndros at 2.1 mg once daily one hour before dinner or at bedtime to reduce the risk of central nervous system (CNS) symptoms. Dosing later in the day may reduce the frequency of CNS adverse reactions. 

    Dosage titration: If tolerated and further therapeutic effect is desired, the dosage may be increased gradually to 2.1 mg one hour before lunch and 4.2 mg one hour before dinner. Increase the dose of Syndros gradually in order to reduce the frequency of dose-related adverse reactions. Most patients respond to 2.1 mg twice daily, but the dose may be further increased to 4.2 mg one hour before lunch and 4.2 mg one hour before dinner, as tolerated to achieve a therapeutic effect. The maximum dosage is 8.4 mg twice daily.

    Nausea and vomiting associated with cancer chemotherapy in adult patients who failed conventional antiemetics:

    Starting dosage: The recommended starting dosage of Syndros is 4.2 mg/m2 orally administered one to three hours prior to chemotherapy and then every two to four hours after chemotherapy for a total of four to six doses per day. In elderly patients, consider initiating Syndros at 2.1 mg/m2 once daily one to three hours prior to chemotherapy to reduce the risk of CNS symptoms. Because food delays the absorption of Syndros, administer the first dose on an empty stomach at least 30 minutes before eating. Subsequent doses can be taken without regard to meals. Because food can substantially change the systemic exposure to dronabinol and its active metabolite, the timing of dosing in relation to meal times should be kept consistent for each chemotherapy cycle, once the dosage has been determined from the titration process.

    Dosage titration: The dosage can be titrated to clinical response during a chemotherapy cycle or subsequent cycles, based upon initial effect, as tolerated to achieve a clinical effect, in increments of 2.1 mg/m2. The maximum dosage is 12.6 mg/m2 per dose for four to six doses per day. Monitor patients for adverse reactions and consider decreasing the dose to 2.1 mg once daily one to three hours prior to chemotherapy to reduce the risk of CNS adverse reaction.

    Clinical Trial Results

    The effectiveness of Syndros has been established based on studies of dronabinol capsules for the treatment of anorexia associated with weight loss in patients with AIDS and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. 

     

     

    Approval Date: 2016-07-01
    Company Name: Insys Therapeutics
    Back to Listings

    Upcoming Events

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • tablet

      Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

    • Diversity-360x240.png

      Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing